| Budget Amount *help |
¥17,160,000 (Direct Cost: ¥13,200,000、Indirect Cost: ¥3,960,000)
Fiscal Year 2019: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Fiscal Year 2018: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Fiscal Year 2017: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2016: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2015: ¥7,800,000 (Direct Cost: ¥6,000,000、Indirect Cost: ¥1,800,000)
|
|---|
| Outline of Final Research Achievements |
We succeeded in improving the MRI sensitivity of Xe by introducing a newly developed high-power, narrow-band laser to our home-built continuous-flow type apparatus for producing hyperpolarized xenon (HPXe), which achieved a maximum polarization level of 84%.. Based on this apparatus, a unique HPXe MRI pulmonary functional diagnostic system for small animals was constructed. Using this system, we performed preclinical evaluation for refractory lung diseases such as chronic obstructive pulmonary disease and pulmonary fibrosis, and found ethyl pyruvate (EP) as a novel drug candidate. Furthermore, the mechanism of EP efficacy was investigated and suggested to be associated with down-regulating the expression of HMGB1, which is one of damage-associated molecular patterns, through inhibition of NF-kB, leading to wound healing of alveolar tissue and improvement of lung function.
|
